点击蓝字 关注我们
前言
2026年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于1月8日至10日（当地时间）在加利福尼亚州旧金山盛大召开。作为全球消化肿瘤领域的顶尖学术盛会，大会旨在为全球肿瘤学者分享前沿研究成果、交流临床实践经验，传递该领域的最新进展与发展趋势。
根据已披露的摘要标题，在消化系统肿瘤领域，共有86项中国研究强势登场，广泛涵盖多个癌种。特此整理，期待与广大读者一同聆听即将响起的中国强音。
胃食管癌
Oral Abstract Session
01
摘要号：282
Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial.
围手术期PD-1抗体特瑞普利单抗联合化疗对比单纯化疗治疗局部进展期胃癌或胃食管结合部癌：前瞻性、随机、II期NEOSUMMIT-01试验的3年随访结果
讲者：袁庶强 | 中山大学肿瘤防治中心
胃食管癌
Rapid Oral Abstract Session
01
摘要号：286
Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase Ilb study (TERRIFIC).
替雷利珠单抗联合放化疗（CRT）对比CRT或化疗（CT）作为局部进展期胃/胃食管结合部腺癌（GC/GEJC）患者新辅助治疗的多中心、随机对照、开放性IIb期研究（TERRIFIC）
讲者：魏嘉 | 南京鼓楼医院
02
摘要号：289
Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage I-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial.
辅助奥沙利铂联合S-1（SOX方案）对比单用S-1治疗I-III期胃或胃食管结合部腺癌患者的随机、开放标签、III期临床试验（CAPITAL研究）。
讲者：聂润聪 | 中山大学肿瘤防治中心
03
摘要号：291
SOX (tegafur plus oxaliplatin) plus anti-PD-1 antibody with or without CAR-like T cell immunotherapy in the treatment of patients with previously untreated metastatic gastric cancer/gastroesophageal junction adenocarcinoma: A multicenter, open-label, randomized, controlled, phase Il trial.
SOX（替吉奥联合奥沙利铂）方案联合抗PD-1抗体治疗，辅以或不辅以类CAR-T细胞免疫疗法，用于既往未经治疗的转移性胃癌/胃食管结合部腺癌患者：一项多中心、开放标签、随机对照的II期临床试验。
讲者：Qin Lin | 南京鼓楼医院
胃食管癌
Poster session
01
摘要号：304
Real-word treatment patterns and biomarker testing landscape of locally advanced gastric/gastroesophageal junction cancer (LA GC/GEJC) in China (SURPASS study).
中国局部晚期胃癌/胃食管交界处癌症(LAGC/GEJC)的真实世界治疗模式和生物标志物检测格局(SURPASS研究)
讲者：苏丹 | 哈尔滨医科大学附属肿瘤医院
02
摘要号：312
A cohort study of concurrent chemoradiotherapy combined with or without immune checkpoint inhibitor in locally advanced esophageal cancer.
一项关于局部晚期食管癌同步放化疗联合或不联合免疫检查点抑制剂的队列研究
讲者：Yiping Lin | 南方医科大学南方医院
03
摘要号：314
Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial.
阿得贝利单抗联合或不联合诱导化疗序贯同步放化疗治疗不可切除局部晚期食管鳞状细胞癌（RICE）：一项前瞻性II期临床试验
讲者：Shuyi Wu | 中山大学肿瘤防治中心
04
摘要号：337
A novel self-controlled electroacupuncture helmet for chemotherapy-induced cognitive impairment: Results from a prospective randomized trial.
一款用于化疗所致认知障碍的新型自控电针头盔：来自前瞻性随机试验的结果。
讲者：Yongling Gong | 南京市第一医院
05
摘要号：344
Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastrosophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase Il trial.
新辅助阿得贝利单抗联合SOX方案和白蛋白结合型紫杉醇治疗可切除局部晚期胃及胃食管结合部腺癌：一项多中心、单臂、前瞻性II期临床试验。
讲者：Pin Liang | 大连医科大学附属第一医院
06
摘要号：348
Low-dose radiotherapy followed by chemoimmunotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A phase II STIMULATION-01 clinical trial.
低剂量放疗序贯化学免疫疗法用于局部晚期食管鳞状细胞癌的新辅助治疗：一项II期STIMULATION-01临床试验。
讲者：Yong Yuan | 四川大学华西医院
07
摘要号：360
Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.
经匹配调整的间接比较：呋喹替尼与雷莫西尤单抗在晚期胃癌或胃食管结合部腺癌中的疗效对比。
讲者：Nan An | 中山大学肿瘤防治中心
08
摘要号：364
A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma.
一项评估HLX43（一种抗PD-L1抗体药物偶联物）在复发性/转移性食管鳞状细胞癌中疗效与安全性的多中心、随机化II期临床研究。
讲者：Linlin Wang | 山东第一医科大学附属肿瘤医院
09
摘要号：368
A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma.
一项关于LBL-007（抗LAG-3抗体）联合替雷利珠单抗（抗PD-1抗体）及化疗作为不可切除局部晚期/转移性食管鳞状细胞癌患者一线治疗的II期临床研究。
讲者：巴一 | 北京协和医学院
10
摘要号：369
Phase Ib/ll study of fruquintinib combined with SOX and toripalimab in advanced metastatic gastric/gastrosophageal junction adenocarcinoma (GC/GEJC).
呋喹替尼联合SOX方案及特瑞普利单抗治疗晚期转移性胃/胃食管结合部腺癌（GC/GEJC）的Ib/II期临床研究。
讲者：孟祥瑞 | 郑州大学第一附属医院
11
摘要号：371
Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase Il trial NEOCRTEC1901.
局部晚期食管鳞状细胞癌新辅助放化疗联合抗PD-1抗体治疗的三年预后及多组学生物标志物发现——来自II期临床试验NEOCRTEC1901的研究结果。
讲者：Zihang Mai | 中山大学
12
摘要号：376
Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (CRT) versus CRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study.
贝莫苏拜单抗（BEN）联合同步放化疗（CRT）与单纯CRT作为食管鳞状细胞癌（ESCC）新辅助治疗的初步结果：一项多中心随机研究。
讲者：Han Tang | 湖北省中山医院
13
摘要号：377
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase II trial (SYLT-023).
替雷利珠单抗联合POFI方案作为晚期胃/胃食管结合部腺癌（AGC）一线治疗：单臂、开放标签II期试验（SYLT-023）的更新数据
讲者：Liyu Su | 福建省肿瘤医院
14
摘要号：382
Efficacy and safety of disitamab vedotin (RC48) in combination with sintilimab and XELOX for perioperative therapy of G/GEJ cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase Il study.
维迪西妥单抗（RC48）联合信迪利单抗及XELOX方案用于HER2过表达型胃/胃食管结合部癌围手术期治疗的疗效与安全性：一项前瞻性单臂II期研究的初步结果。
讲者：Ying Liu | 郑州大学附属肿瘤医院
15
摘要号：386
Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective, single-arm, open-label, real-world study.
帕博利珠单抗联合化疗作为转化疗法治疗伴有颈部淋巴结转移的食管鳞状细胞癌：一项单中心、前瞻性、单臂、开放标签的真实世界研究。
讲者：Qi Ding | 中国科学技术大学附属第一医院
16
摘要号：391
Clinical significance of oligometastatic esophageal squamous cell carcinoma: A retrospective cohort study.
寡转移性食管鳞状细胞癌的临床意义：一项回顾性队列研究。
讲者：Tsung-Che Wu | 台湾大学医学院附属医院新竹分院
17
摘要号：395
Final results of a phase Il study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastrosophageal junction adenocarcinoma (GC/GEJC).
呋喹替尼联合信迪利单抗作为晚期胃癌及胃食管结合部腺癌（GC/GEJC）二线治疗的II期研究最终结果。
讲者：Min Jin | 华中科技大学同济医学院
18
摘要号：398
Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers.
IMC002（一种基于VHH的抗CLDN18.2 CAR-T疗法）治疗胃食管癌的I期有效性和安全性临床试验
讲者：Chao Li | 中国人民解放军总医院
19
摘要号：404
Updated results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Il clinical trial.
安罗替尼联合派安普利单抗与白蛋白结合型紫杉醇一线治疗晚期食管鳞状上皮细胞癌(ESCC)的最新研究结果：一项单臂、开放标签的II期临床试验
讲者：Zhiwei Chang | 郑州大学第一附属医院
20
摘要号：406
Proximal gastrectomy versus total gastrectomy in locally advanced upper gastric cancer after neoadjuvant chemotherapy combined with tislelizumab: The preliminary results of a multicenter, prospective, randomized, phase 3 clinical trial.
新辅助化学疗法联合替雷利珠单抗治疗后，局部进展期胃上部癌行近端胃切除术与全胃切除术比较：一项多中心、前瞻性、随机、III期临床试验的初步结果
讲者：王桂华 | 华中科技大学同济医学院
21
摘要号：407
Cadonilimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy as first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS<5: A propensity-matched, retrospective cohort study.
卡度尼利单抗联合化疗对比PD-1抑制剂联合化疗作为PD-L1 CPS<5的晚期胃癌或胃食管结合部癌一线治疗：一项倾向匹配的回顾性队列研究
讲者：Duqin Zhao | 浙江省肿瘤医院
22
摘要号：410
Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study.
阿得贝利单抗联合白蛋白结合型紫杉醇和奈达铂作为局部晚期可切除食管鳞状细胞癌的新辅助治疗：一项多中心、单臂、II期临床研究
讲者：Jianqun Ma | 哈尔滨医科大学附属肿瘤医院
23
摘要号：411
A prospective, single-arm phase Il study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma.
一项前瞻性、单臂II期研究：评估曲拉西利联合免疫治疗与化疗作为转移性/复发性食管鳞状细胞癌一线治疗方案的效果。
讲者：Yi Wang | 四川省肿瘤医院
24
摘要号：412
Interim analysis of immunomodulatory low-dose radiotherapy plus chemoimmunotherapy as conversion therapy for locally advanced potentially/borderline resectable esophageal squamous cell carcinoma (ROICE trial): A phase Il single-arm study.
局部晚期潜在/临界可切除食管鳞状细胞癌转化治疗中免疫调节性低剂量放疗联合化学免疫疗法的中期分析（ROICE试验）：一项II期单臂研究
讲者：任伟 | 南京鼓楼医院
25
摘要号：424
Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients.
SMARCA4缺陷型胃癌患者的临床结局与免疫微环境
讲者：Hongyong He | 复旦大学附属中山医院
26
摘要号：435
Concordance of programmed death-ligand 1 (PD-L1) status in primary esophageal squamous cell carcinoma (ESCC) and matched visceral metastases.
原发性食管鳞状细胞癌（ESCC）及其匹配内脏转移灶中程序性死亡配体1（PD-L1）状态的一致性
讲者：Jhe-Cyuan Guo | 台湾大学医学院附设医院
27
摘要号：452
Non-invasive early detection of gastric cancer using red blood cell DNA genomic signature: A multi-center validation study.
利用红细胞DNA基因组特征无创早期检测胃癌：一项多中心验证研究
讲者：Haobo Sun | 西湖大学
胃食管癌
Trials in Progress Poster Session
01
摘要号：TPS463
SYLT-030: Efficacy and safety of tislelizumab plus mFOLFOX6 versus tislelizumab plus POF (paclitaxel + mFOLFOX6) as first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): A multicenter, open-label, randomized phase Ill trial.
SYLT-030：替雷利珠单抗联合mFOLFOX6对比替雷利珠单抗联合POF（紫杉醇+mFOLFOX6）作为晚期胃/胃食管结合部腺癌（AGC）一线治疗的疗效与安全性：一项多中心、开放标签、随机III期临床试验。
讲者：林榕波 | 福建省肿瘤医院
肝胆胰肿瘤
Rapid Oral Abstract Session
01
摘要号：655
Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).
派安普利单抗（PD-1 抑制剂）、安罗替尼（抗血管生成靶向药）、白蛋白结合型紫杉醇与吉西他滨联合作为转移性胰腺癌一线方案：一项多中心随机对照试验（RCT-PAAG）
讲者：杜娟 | 南京鼓楼医院
肝胆胰肿瘤
Poster session
01
摘要号：485
Combining the albumin-bilirubin (ALBI) score and ECOG performance status for enhanced prognostication in advanced biliary tract cancer treated with durvalumab-based immunochemotherapy.
联合白蛋白-胆红素（ALBI）评分与 ECOG 体能状态，优化度伐利尤单抗为基础的免疫化疗治疗晚期胆道癌的预后评估
讲者：Chi-Chen Lan | 长庚纪念医院
02
摘要号：496
Pathological complete response after systemic conversion therapy and curative resection in initially unresectable hepatocellular carcinoma: Feasibility of a tumor-free for drug-free strategy.
初始不可切除肝细胞癌经全身转化治疗联合根治性切除后的病理完全缓解：“无瘤即停药” 策略的可行性
讲者：王骏成 | 中山大学肿瘤防治中心
03
摘要号：499
Efficacy and safety of durvalumab plus gemcitabine/cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.
度伐利尤单抗联合吉西他滨/顺铂在混合型肝细胞-胆管癌与胆管癌中的疗效与安全性
讲者：Yu-Wei Hsu | 长庚纪念医院
04
摘要号：502
External validation of MAGIC-D in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy.
MAGIC-D 模型在接受度伐利尤单抗联合化疗的台湾晚期胆道系统癌患者中的外部验证
讲者：Chi-Lin Hsieh | 长庚纪念医院
05
摘要号：506
Transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab versus TACE alone in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis.
经动脉化疗栓塞（TACE）联合信迪利单抗与贝伐珠单抗 vs 单用 TACE 治疗巴塞罗那临床肝癌分期B期不可切除肝细胞癌：一项回顾性倾向评分匹配分析
讲者：蔡鸿杰 | 中山大学附属第一医院
06
摘要号：510
Pattern of progression in advanced hepatocellular carcinoma treated with immunotherapy.
免疫治疗下晚期肝细胞癌的进展模式
讲者：Thomas Yau | 香港大学
07
摘要号：511
A simple ABC score for prognosis stratification and treatment selection in advanced hepatocellular carcinoma.
用于晚期肝细胞癌预后分层与治疗选择的简易ABC评分
讲者：Yung-Yeh Su | 国家卫生研究院
08
摘要号：536
Toripalimab plus hepatic artery infusion chemotherapy in hepatocellular carcinoma patients of Barcelona Clinic Liver Cancer stage C: A biomolecular exploratory, phase Il trial.
特瑞普利单抗联合肝动脉灌注化疗用于巴塞罗那临床肝癌C期肝细胞癌患者：一项生物分子探索性II期临床试验。
讲者：Rongce Zhao | 中山大学肿瘤防治中心
09
摘要号：539
Optimizing the sequencing and timing of transarterial chemoembolization and systemic therapy in advanced hepatocellular carcinoma.
优化经动脉化疗栓塞与系统式治疗在晚期肝细胞癌中的序贯与时机安排。
讲者：黄莹莹 | 北京医院
10
摘要号：540
Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable HCC (START-FIT using STRIDE): A single-arm, phase Il, multi-centre study.
序贯性经动脉化疗栓塞术联合体部立体定向放射治疗，随后采用单次tremelimumab联合固定间隔durvalumab免疫疗法治疗局部晚期不可切除肝细胞癌（START-FIT方案应用STRIDE策略）：一项单臂、II期、多中心临床研究。
讲者：Chi Leung Chiang | 香港大学
11
摘要号：549
Donafenib and sintilimab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A phase Il, biomarker exploratory study (Dosin TACE).
多纳非尼与信迪利单抗联合经导管动脉化疗栓塞治疗不可切除肝细胞癌：一项II期生物标志物探索性研究（Dosin TACE）。
讲者：Xiaoyun Hu | 南方医科大学南方医院
12
摘要号：557
Adjuvant sintilimab plus capecitabine in resected extrahepatic cholangiocarcinoma: Interim report of a single-arm, prospective phase Il study.
辅助性信迪利单抗联合卡培他滨治疗肝外胆管癌切除术后的中期报告：一项单臂前瞻性II期研究。
讲者：Jinxue Zhou | 郑州大学附属肿瘤医院
13
摘要号：564
Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase Il clinical study.
信迪利单抗联合仑伐替尼对比肝动脉灌注化疗（HAIC）用于可切除性肝细胞癌伴高复发风险患者的新辅助治疗：一项前瞻性、双臂、随机、II期临床研究。
讲者：Feng Fang | 天津医科大学肿瘤医院
14
摘要号：565
Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintlimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase Il clinical study.
肝动脉灌注化疗（HAIC）或仑伐替尼联合信迪利单抗作为高复发风险可切除IB期孤立性肝细胞癌新辅助治疗的安全性与有效性：一项前瞻性、随机、双队列、探索性II期临床研究。
讲者：Yunlong Cui | 天津医科大学肿瘤医院
15
摘要号：569
Outcomes of sarcomatoid hepatocellular carcinoma patients treated with immunotherapy: A multi-institutional retrospective study.
肉瘤样肝细胞癌患者接受免疫治疗的疗效：一项多机构回顾性研究。
讲者：Tsung-Hao Liu | 台湾大学医学院
16
摘要号：601
Early detection of hepatocellular carcinoma using red blood cell DNA signatures.
通过红细胞DNA特征早期检测肝细胞癌。
讲者：XIngyun Yao | 西湖大学生命科学学院
17
摘要号：634
Real-world efficacy and safety of surufatinib in advanced neuroendocrine neoplasm.
索凡替尼在晚期神经内分泌肿瘤中的真实世界疗效与安全性。
讲者：Jiang Long | 上海市第一人民医院
18
摘要号：710
Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
KRAS G12D高选择性抑制剂TSN1611在晚期实体瘤患者中的I/II期研究更新结果。
讲者：Jian Li | 北京大学肿瘤医院
19
摘要号：711
Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial.
术前NALIRIFOX方案对比直接手术在高风险可切除胰腺癌中的疗效：一项随机多中心临床试验。
讲者：Shiwei Guo | 上海长海医院
20
摘要号：718
Preliminary efficacy and biomarker analysis of CLDN18.2-targeted ADC combined with the NET inhibitor sivelestat in female patients with advanced CLDN18.2-positive pancreatic adenocarcinoma.
CLDN18.2靶向抗体偶联药物联合NET抑制剂西维来司他钠治疗晚期CLDN18.2阳性胰腺癌女性患者的初步疗效与生物标志物分析。
讲者：Jingrui Yan | 天津医科大学肿瘤医院
21
摘要号：719
Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase Il trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer.
ALTER-PA-001试验初步结果：一项多中心、开放标签、随机II期临床试验，评估安罗替尼联合贝莫苏拜单抗与AG方案对比AG方案作为转移性胰腺癌一线治疗的疗效。
讲者：Jiujie Cui | 上海交通大学医学院附属仁济医院
22
摘要号：720
Efficacy and safety of liposomal irinotecan in patients with advanced pancreatic cancer: A prospective, multicenter, real-world study.
脂质体伊立替康在晚期胰腺癌患者中的疗效与安全性：一项前瞻性、多中心、真实世界研究。
讲者：Jin Xu | 复旦大学附属肿瘤医院
23
摘要号：744
A real-world study of claudin 18.2 (CLDN18.2) association with molecular subtypes, mutations/biomarkers, immune landscapes, and gene signatures and prognostic value in pancreatic ductal adenocarcinoma (PDAC).
一项关于紧密连接蛋白18.2（CLDN18.2）与胰腺导管腺癌（PDAC）分子亚型、突变/生物标志物、免疫微环境、基因特征关联及其预后价值的真实世界研究。
讲者：Guoqiang Zhang | 安斯泰来制药集团
24
摘要号：748
A phase 2 study of vilanterol in combination with a CLDN18.2 bispecific antibody in patients with advanced CLDN18.2-positive pancreatic ductal adenocarcinoma (PDAC).
维兰特罗联合Claudin18.2双特异性抗体治疗晚期Claudin18.2阳性胰腺导管腺癌（PDAC）的II期研究
讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院
25
摘要号：749
A phase 2 study of STING agonist ADU-S100 combined with a CLDN18.2 bispecific antibody in patients with advanced pancreatic cancer.
STING激动剂ADU-S100联合CLDN18.2双特异性抗体治疗晚期胰腺癌的II期研究
讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院
26
摘要号：750
Predictive value of CLDN18.2+CD8+ T cells in peripheral blood and tumor tissue for immunotherapy response and survival in gastric and pancreatic cancers.
外周血和肿瘤组织中CLDN18.2+CD8+ T细胞对胃癌和胰腺癌免疫治疗反应及生存情况的预测价值
讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院
27
摘要号：751
Multicenter prospective validation of PanClaudinAI: An AI for predicting Claudin 18.2 from CT in pancreatic cancer.
PanClaudinAI的多中心前瞻性验证：一种基于CT预测胰腺癌中Claudin 18.2的人工智能
讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院
肝胆胰肿瘤
Trials in Progress Poster Session
01
摘要号：TPS607
Curative therapy after atezolizumab and bevacizumab treatment for unresectable hepatocellular carcinoma: A multinational retrospective study.
阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌后的根治性治疗：一项多国回顾性研究。
讲者：Yu-Yun Shao | 台湾大学医学院附设医院
结直肠癌
Oral Abstract Session
01
摘要号：477
Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.
帕博利珠单抗辅助治疗经手术切除或局部消融后获得完全影像学缓解的肝细胞癌患者：III期 KEYNOTE-937 研究
讲者：陈林 | 香港中文大学
结直肠癌
Poster session
01
摘要号：21
Validation of CanCatch Surf assay for tissue-agnostic detection of minimal residual disease in colorectal cancer.
CanCatch Surf 检测方法在结直肠癌中泛组织微小残留病检测的验证研究
讲者：Shaoyong Dong | 河北大学附属医院
02
摘要号：53
Efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX or FOLFIRI plus drug-eluting bead transarterial chemoembolization in unresectable colorectal liver metastases.
FOLFOX或FOLFIRI方案肝动脉灌注化疗联合载药微球经动脉化疗栓塞治疗不可切除结直肠癌肝转移的疗效与安全性
讲者：刘宝将 | 北京大学肿瘤医院
03
摘要号：71
Anastomotic leak and oncologic outcomes after colorectal cancer resection: A real-world analysis.
结直肠癌切除术后吻合口瘘与肿瘤学结局的真实世界分析
讲者：Tina T. Lin | 中山医学大学
04
摘要号：118
EMB-01, a tetravalent anti-EGFR/cMET bispecific antibody, in the left-sided, RAS/BRAF wild-type, late-line metastatic colorectal cancer: Subgroup analysis of baseline characteristics and response from a phase 1/2 study.
四价抗EGFR/cMET双特异性抗体EMB-01用于左侧、RAS/BRAF野生型后线转移性结直肠癌：1/2期研究中基线特征与疗效的亚组分析
讲者：李健 | 北京大学肿瘤医院
05
摘要号：119
Neoadjuvant chemotherapy and serplulimab in MSS/pMMR locally advanced rectal cancer (FIRM): A phase II trial.
新辅助化疗联合斯鲁利单抗用于MSS/pMMR局部晚期直肠癌（FIRM 研究）：一项II期临床试验
讲者：吴庭玉 | 上海交通大学医学院附属新华医院
06
摘要号：121
Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair metastatic colorectal cancer: Updated survival analysis and safety outcomes from a multicenter, single-arm, phase 2 study (SYLT-026).
卡度尼利单抗联合FOLFIRINOX方案与贝伐珠单抗作为微卫星稳定/错配修复功能正常转移性结直肠癌的一线治疗：一项多中心单臂II期研究（SYLT-026）的生存分析更新及安全性结局
讲者：Yi Yin | 福建省肿瘤医院
07
摘要号：124
Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study.
西妥昔单抗（Q3W）联合卡培他滨作为KRAS/BRAF野生型转移性结直肠癌一线维持治疗的疗效与安全性：一项Ib期剂量递增研究
讲者：谢晓煜 | 中山大学附属第六医院
08
摘要号：128
Short-course radiotherapy (SCRT) followed by immunochemotherapy plus fruquintinib as the total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).
短程放疗联合免疫化疗加呋喹替尼作为局部晚期直肠癌的全程新辅助治疗（TNT）：一项多中心、单臂、开放标签的II期研究（UNION TNT）
讲者：张涛 | 华中科技大学同济医学院附属协和医院
09
摘要号：131
Progression-free survival with the ICE regimen in refractory RAS/BRAF wild-type and MSS mCRC patients.
ICE方案用于难治性RAS/BRAF野生型及微卫星稳定转移性结直肠癌患者的无进展生存期
讲者：黄莹莹 | 北京医院
10
摘要号：145
Surgical efficacy of neoadjuvant mono-immunotherapy for T₄-deficient mismatch repair colon cancer: A prospective, single-arm, phase II trial.
新辅助单药免疫治疗用于T₄期错配修复缺陷型结肠癌的手术疗效：一项前瞻性、单臂II期试验
讲者：孙振 | 北京协和医院
11
摘要号：147
Neoadjuvant short-course radiotherapy combined with CAPOX and PD-1 inhibitor for MSS/pMMR high-risk locally advanced colon cancer: A randomized, prospective, multicentre, phase II trial (TORCH-C).
新辅助短程放疗联合CAPOX方案与PD-1抑制剂用于MSS/pMMR 高危局部晚期结肠癌：一项随机、前瞻性、多中心II期试验（TORCH-C）
讲者：张慧 | 复旦大学附属肿瘤医院
12
摘要号：148
Second-line Irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study.
奥沙利铂/5-氟尿嘧啶治疗失败的RAS/RAF野生型转移性结直肠癌患者中，二线伊立替康序贯三线西妥昔单抗联合伊立替康 vs 二线西妥昔单抗联合伊立替康的对比：一项随机II期研究
讲者：李文桦 | 复旦大学附属肿瘤医院
13
摘要号：154
Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial.
循环肿瘤DNA指导西妥昔单抗联合伊立替康在国内RAS/BRAF野生型转移性结直肠癌中的再挑战治疗：一项II期试验
讲者：李宇红 | 中山大学肿瘤防治中心
14
摘要号：157
Regorafenib combined with trifluridine/tipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial.
瑞戈非尼联合曲氟尿苷/替匹嘧啶 vs 瑞戈非尼单药治疗难治性转移性结直肠癌（FDZL-REGOT 研究）：一项随机II期试验
讲者：王辰辰 | 复旦大学附属肿瘤医院
15
摘要号：173
Sequencing fruquintinib and trifluridine/tipiracil to improve outcomes in the real-world management of MMR-proficient, chemo-refractory colorectal cancer in Hong Kong.
香港地区错配修复功能正常、化疗难治性结直肠癌的真实世界管理中，呋喹替尼与曲氟尿苷/替匹嘧啶的序贯治疗以改善结局
讲者：Jenny Lo | 香港大学
16
摘要号：184
Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Data from the TAPISTRY trial.
普拉替尼在RET融合阳性实体瘤中的疗效与安全性：来自TAPISTRY试验的数据
讲者：Chia-Chi Lin | 台湾大学
17
摘要号：188
Influence of the NECTIN2-TIGIT axis on resistance to PD-L1 blockade combined with chemoradiotherapy in MSS locally advanced rectal cancer.
NECTIN2-TIGIT轴对微卫星稳定型局部晚期直肠癌中PD-L1抑制剂联合放化疗耐药性的影响
讲者：Zhehui Zhu | 复旦大学附属中山医院
18
摘要号：206
Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS/pMMR metastatic colorectal cancer: A multicenter biomarker study.
微卫星稳定/错配修复功能正常转移性结直肠癌中酪氨酸激酶抑制剂联合免疫治疗应答的多组学特征分析：一项多中心生物标志物研究
讲者：Zhihao Hu | 陆军军医大学
19
摘要号：299
Single-cell sequencing to reveal immune features of treatment response to neoadjuvant chemoradiotherapy plus immunotherapy in locally advanced rectal cancer.
单细胞测序揭示局部晚期直肠癌中新辅助放化疗联合免疫治疗应答的免疫特征
讲者：Qianyu Wang | 中国人民解放军总医院
20
摘要号：230
Influence of multiomics on tumor microenvironment remodeling in locally advanced rectal cancer following neoadjuvant chemoradiotherapy plus immunotherapy.
多组学对局部晚期直肠癌新辅助放化疗联合免疫治疗后肿瘤微环境重塑的影响
讲者：Na Tian | 中国人民解放军总医院
结直肠癌
Trials in Progress Poster Session
01
摘要号：TPS258
Phase II trial of neoadjuvant short-course radiotherapy followed by ivonescimab with or without chemotherapy in locally advanced rectal cancer (TRIUNITE-03).
局部晚期直肠癌中新辅助短程放疗序贯依沃西单抗联合或不联合化疗的II期试验（TRIUNITE-03 研究）
讲者：Haode Shen | 陆军军医大学陆军特色医学中心 (大坪医院)
02
摘要号：TPS261
TRIUNITE-02: A phase 2, open-label, randomized study of neoadjuvant CAPEOX plus tislelizumab and chidamide versus CAPEOX alone in previously untreated, resectable, locally advanced mismatch repair-proficient/microsatellite stable colon cancer.
TRIUNITE-02研究：未接受过治疗、可切除的局部晚期错配修复功能正常/微卫星稳定型结肠癌中，新辅助CAPEOX方案联合替雷利珠单抗与西达本胺 vs 单用 CAPEOX 的II期开放标签随机研究
讲者：Zhuo Chen | 陆军军医大学陆军特色医学中心 (大坪医院)
03
摘要号：TPS271
Reducing the resection range after neoadjuvant therapy for locally advanced upper rectal and rectosigmoid junction cancers (RESET): A prospective, multicenter, randomized controlled phase 3 study.
局部晚期高位直肠癌与直肠乙状结肠交界处癌新辅助治疗后缩小切除范围（RESET 研究）：一项前瞻性、多中心、随机对照III期研究
讲者：Zhiming Liu | 中山大学附属第六医院
04
摘要号：TPS272
Phase II trial of neoadjuvant short-course radiotherapy followed by ivonescimab with or without chemotherapy in locally advanced rectal cancer (TRIUNITE-03).
局部晚期直肠癌中新辅助短程放疗序贯依沃西单抗联合或不联合化疗的II期试验（TRIUNITE-03 研究）
讲者：Haode Shen | 陆军军医大学陆军特色医学中心 (大坪医院)
备注：排名不分先后，按照摘要号进行排序
如有遗漏或任何问题，请给我们留言~
声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。
来源：医脉通消化系统肿瘤
编辑：Lagertha
审核：素问
